Drug Detail

Information about Oleandrin

Generic Name	Oleandrin
IND	PBI-05204
Brand Name (US)
Manufacturer	Phoenix Biotechnology, Inc.
Drug Type	Cardiac glycoside
Delivery	Oral
Approval Status	Phase 1
Indications
Overall Strategy	Oncogenic Signal Path Based
Strategy
Drug Category	Cardenolide

This is an oral version of an oleandrin extract.Oleandrin inhibits the {alpha}-3 subunit Na-K ATPase pump.
In the phase I solid tumor trial (no GIST), of the 15 evaluable pts, 3 had stable disease for > 4 months, with bladder, colorectal, and fallopian tube cancer pts having an 11, 16, and 10% reduction by RECIST respectively. PKs initially show dose-dependent peak plasma oleandrin concentrations are reached at 2–4 hr following administration with > 50% cleared in 6 hrs.